Welcome to vnonline.co.uk

vnonline.co.uk provides the veterinary nursing profession with the latest news and industry developments, as well as events, resources, learning materials and careers.

Our website is dedicated to veterinary nurses and we strive to provide a platform where you can voice and explore your interests.

Not a member yet? Sign up for free!

Click here to become a member

Posted: 9th June 2015

Rise in Augmentin adverse reaction reports

GlaxoSmithKline said that it has not altered the manufacture of the product and it is not aware of any batch defects.

Practices encouraged to report all adverse events to the VMD

There has been a significant rise is the number of adverse reaction reports relating to Augmentin Intravenous Powder for Solution for Injection, according to the Veterinary Medicines Directorate (VMD).

In a letter to Veterinary Record (Vol. 176, No. 23) Gillian Diesel from the VMD said that over the past three months, the organisation has seen a 'significantly higher' number of reports relating to Augmentin.

"They all involved hypersensitivity reactions, including allergic oedema, urticaria and allergic pruritus," writes Gillian.

"We notified veterinary practices of a similar issue in 2011 concerning Co-amoxiclav, which also contains amoxicillin and clavulanate."

Augmentin is authorised for use in humans and is authorised for use by veterinary surgeons under the cascade system. It is not authorised for use in animals, so no safety or efficacy studies have been carried out relating to its use in animals.

The VMD spoke to the manufacturer, GlaxoSmithKline and the Medicines and Healthcare Products Regulator Agency (MHRA).

GlaxoSmithKline said that it has not altered the manufacture of the product and is not aware of any batch defects. They asked some practices to send them samples of a batch for testing, which confirmed that the product was within manufacturing specifications.

GlaxoSmithKline and the MHRA also said they were not aware of a rise in the number of reactions or reports from humans relating to the product.

"We would like to encourage practices to report all adverse events to the VMD using our online reporting form," added Gillian.

"As Augmentin is not authorised for use in animals, GlaxoSmithKline has no obligation to investigate these case or report them to the VMD.

"We would also like to remind vets that any human adverse reactions to authorised human medicines should be report to the MHRA."

Become a member or log in to add this story to your CPD history

Share with others

Bury St Edmunds voted UK's most dog-friendly town
26th November 2024

Brazil should address donkey skin trade, says Donkey Sanctuary
26th November 2024

Canine gene database to enhance biomedical research
26th November 2024

Mind Matters invites research abstracts for symposium
26th November 2024

Birmingham Dogs Home makes urgent appeal
Birmingham Dogs Home has issued an urgent winter appeal as it faces more challenges over the Christmas period.

The rescue centre has seen a dramatic increase in dogs coming into its care, and is currently caring for over 200 dogs. With rising costs and dropping temperatures, the charity is calling for urgent support.

It costs the charity £6,000 per day to continue its work.

Fi Harrison, head of fundraising and communications, said: "It's heart-breaking for our team to see the conditions some dogs arrive in. We really are their last chance and hope of survival."

More information about the appeal can be found here.

Advertise on vnonline

If you are interested in advertising on vnonline.co.uk or our weekly enews, click here

Welcome to vnonline.co.uk

Not a member yet? Sign up for free!

Log in to vnonline